Buscar
Congreso SOLACI

Búsqueda de: prasugrel

Si no está conforme con los resultados, inténtelo de nuevamente.
Antiplatelet

AHA 2025 | TUXEDO-2: Post-PCI Antiplatelet Management in Diabetic Patients with Multivessel Disease — Ticagrelor or Prasugrel?

Choosing the optimal P2Y12 inhibitor for diabetic patients with multivessel coronary artery disease undergoing percutaneous coronary intervention...
Dr. Omar Tupayachi -
Ir
Acute coronary syndromes

Abbreviated Dual Antiplatelet Therapy with Prasugrel: 4D-ACS

The optimal duration of dual antiplatelet therapy (DAPT) in acute coronary syndrome (ACS) remains subject to controversy....
Dr. Omar Tupayachi -
Ir
Acute coronary syndromes

EuroPCR 2025 | 4D-ACS Study: One-Month Dual Antiplatelet Therapy Followed by Low-Dose Prasugrel Monotherapy

While dual antiplatelet therapy (DAPT) has long been the standard treatment for managing patients with acute coronary...
Dr. Andrés Rodríguez -
Ir
Acute coronary syndromes

Prehospital Crushed vs. Integral Prasugrel in STEMI Patients with Large Myocardial Area at Risk

Timely percutaneous intervention of STEMI patients effectively reduces MI size and mortality, which currently makes it the...
solaci -
Ir
Antiplatelet

SOLACI-SBHCI 2023 | Patient-centered Selection Anti-platelet Treatment for ACS-PCI Patients: Real World Evidence of Prasugrel – Dr. Roxana Mehran

Read the most outstanding articles from SOLACI-SBHCI 2023 Congress. In this case, check the presentation by Dr. Roxana...
solaci -
Ir
Antiplatelet

Ticagrelor or Prasugrel Post-PCI in Daily Practice Patients

The ISAR-REACT 5 showed a significant reduction in the composite outcome of death, acute myocardial infarction (AMI),...
solaci -
Ir
Acute coronary syndromes

ESC 2021 | ISAR-REACT 5: Prasugrel Superior to Ticagrelor in ACS across Kidney Function Spectrum

When we have to choose between two potent P2Y12 receptor inhibitors for a patient undergoing ACS with...
solaci -
Ir
Acute coronary syndromes

Ticagrelor or Prasugrel for Acute Patients Who Undergo Angioplasty

We are still asking the same question: ticagrelor or prasugrel? With narrow margins between these drugs in...
solaci -
Ir

SOLACI es la organización de referencia del intervencionismo cardiovascular latinoamericano.

Últimas Noticias

Comparison of strategies: NMA of IVUS, OCT, or angiography in complex lesions

Dr. Omar Tupayachi - 0
Percutaneous coronary intervention (PCI) in complex lesions continues to represent a technical challenge in contemporary interventional cardiology. Angiography, although it remains the most widely...

Is upper-limb aerobic training an effective alternative to lower-limb exercise in peripheral artery disease?

Dr. Juan Manuel Pérez - 0
Peripheral artery disease is associated with impaired functional capacity, reduced walking distance, and poorer quality of life, and structured exercise is a class I...

Dynamic Coronary Roadmap: does it really help reduce contrast use?

Dr. Juan Manuel Pérez - 0
Contrast-induced nephropathy remains a relevant complication of percutaneous coronary interventions (PCI), particularly in patients with multiple comorbidities and complex coronary anatomies. Dynamic Coronary Roadmap...

Noticias Institucionales

Advanced Postgraduate Course in Hemodynamics and Interventional Cardiology – 2026 Edition

solaci - 0
Registration is now open for the SOLACI–CACI Advanced Postgraduate Course in Hemodynamics and Interventional Cardiology – 2026 Edition. The program is intended for physicians with...

SOLACI Wishes You Happy Holidays

solaci - 0
From the heart, Happy Holidays! The Latin American Society of Interventional Cardiology wishes all its members and the medical community across the continent a very Merry Christmas...

Condolences on the passing of Cristiam Arancibia

solaci - 0
The Latin American Society of Interventional Cardiology deeply mourns the passing of Lic. Cristiam Arancibia, first Director of the Chapter of Technicians and Nurses,...

Accesos

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Términos de uso -Políticas de privacidad